Hydrea (Hydroxycarbamide)

Hydrea (hydroxycarbamide) is indicated for several hematologic disorders and specific malignancies, where it helps control abnormal cell proliferation and reduce disease‑related complications.

• Sickle cell disease, to decrease the frequency of vaso‑occlusive pain crises.
• Chronic myelogenous leukemia (CML), as part of disease‑modifying therapy.
• Essential thrombocythemia, to lower elevated platelet counts.
• Polycythemia vera, to manage increased red blood cell mass.
• Melanoma, in selected patients as an adjunctive treatment.
• Other myeloproliferative neoplasms, for disease control when standard options are limited.

• Hydroxycarbamide exerts its antineoplastic effect by inhibiting ribonucleotide reductase, the enzyme responsible for converting ribonucleotides to deoxyribonucleotides. This inhibition reduces the intracellular pool of deoxyribonucleic acid (DNA) precursors, leading to decreased DNA synthesis, impaired cell division, and ultimately suppression of rapidly proliferating malignant or abnormal hematopoietic cells. The resulting cell‑cycle arrest predominantly affects cells in the S‑phase, contributing to its therapeutic activity in diseases driven by uncontrolled cell growth.

Hydroxycarbamide may cause a range of adverse reactions, varying from mild to potentially serious.

Common

• Nausea or vomiting.
• Loss of appetite.
• Mild fatigue or weakness.
• Low white blood cell count (leukopenia).
• Low platelet count (thrombocytopenia).

Serious

• Severe bone marrow suppression leading to pancytopenia.
• Acute skin reactions such as Stevens‑Johnson syndrome.
• Significant liver enzyme elevations.
• Rare cases of pulmonary fibrosis.
• Life‑threatening infections due to immunosuppression.

Before starting Hydrea, healthcare providers assess several safety factors to minimize risks and ensure appropriate use.

• Baseline complete blood count and regular monitoring during therapy.
• Assessment of liver and kidney function prior to treatment.
• Caution in patients with pre‑existing bone marrow suppression.
• Avoid use during pregnancy unless benefits outweigh risks; discuss contraception.
• Monitor for signs of infection or bleeding.
• Adjust dose in elderly or frail patients as needed.
• Review patient’s medication history for potential interactions.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or increasing toxicity.

Avoid

• Concurrent use with other myelosuppressive agents (e.g., chemotherapy, azathioprine) that may exacerbate bone‑marrow suppression.
• High‑dose folic acid supplementation, which may reduce hydroxycarbamide effectiveness.

Use with caution

• Anticoagulants (e.g., warfarin) due to potential enhanced bleeding risk.
• Allopurinol, which may increase hydroxycarbamide plasma levels.
• NSAIDs, because of additive gastrointestinal irritation.
• Vaccines containing live attenuated organisms, given immunosuppression.
• Drugs that affect renal excretion (e.g., probenecid) may alter clearance.